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ABSTRACT
Homology-directed genome engineering is limited by
transgene size. Although DNA transposons are more
efficient with large transgenes, random integrations
are potentially mutagenic. Here we present an in vitro
mechanistic study that demonstrates efficient Cas9
targeting of the mariner transposon Hsmar1. Integra-
tions were unidirectional and tightly constrained to
one side of the sgRNA binding site. Further analy-
sis of the nucleoprotein intermediates demonstrated
that the transposase and Cas9 moieties can bind
their respective substrates independently or in con-
cert. Kinetic analysis of the reaction in the presence
of the Cas9 target–DNA revealed a delay between
first and second strand cleavage at the transposon
end. This step involves a significant conformational
change that may be hindered by the properties of
the interdomainal linker. Otherwise, the transposase
moiety behaved normally and was proficient for inte-
gration in vitro and in Escherichia coli. Specific inte-
gration into the lacZ gene in E. coli was obscured by
a high background of random integrations. Neverthe-
less, Cas9 is an attractive candidate for transposon-
targeting because it has a high affinity and long
dwell-time at its target site. This will facilitate a fu-
ture optogenetic strategy for the temporal control of
integration, which will increase the ratio of targeted
to untargeted events.
INTRODUCTION
Biotechnology and medicine are increasingly reliant on our
ability to engineer themammalian genome. Lentiviruses are
useful because gene-delivery across the cell membrane is ef-
ficient and integration of the viral genome provides long-
term transgene expression.However, they aremutagenic be-
cause they integrate at random sites using amechanism sim-
ilar to the cut-and-paste transposons. An alternative strat-
egy for ex vivo applications is to establish genomic safe-
havens for site-specific recombinases such as the phage C31
integrase or the Cre recombinase (1,2). This approach lacks
flexibility because it is limited to transgene integration at a
predetermined site.
Scar-less engineering of a target site must rely on the cell’s
homologous recombination machinery. Although desired
modifications can bemade very precisely, the events are rare
and difficult to recover. One way to boost the rate of recom-
bination by orders of magnitude is to make a DNA double
strand break at the target site (3). This can be achieved using
zinc finger nucleases and transcription activator-like effec-
tor (TALE) nucleases, which can themselves be engineered
to target a user-defined site (4,5). Two significant problems
are the extended lead-times and off-target cleavages. TALE
and zinc finger nucleases have now been largely superseded
by the Cas9 nuclease. It can be programed to target a 20 bp
recognition sequence, simply by providing amatching guide
RNA (gRNA). Off-target cleavage is relatively low and the
long recognition sequence provides ample specificity. How-
ever, homologous recombination remains a limiting factor
because the efficiency falls off as the transgene size increases
(6).
Transposon vectors are widely used for gene delivery ap-
plications (7–11). Although their efficiency falls off as the
cargo size is increased, they are less sensitive to this param-
eter than host-mediated homologous recombination (12–
16). However, like the Lentiviruses, transposon vectors are
mutagenic because the integration sites are essentially ran-
dom.
To combat random integration various groups have at-
tempted to use site-specific DNA binding proteins to target
specific loci. Examples includeMos1, Sleeping Beauty, pig-
gyBac and ISY100 transposases, whichwere variously fused
to zinc finger proteins, TALEs and Gal4 (17–22). Cas9 is an
obvious and attractive candidate for targeting because ex-
tensive base pairing with the target provides a dwell time of
several hours (23). In contrast, most DNA binding proteins
remain bound to their specific sites only for a matter of sec-
onds or minutes.
Previously, there was an unsuccessful attempt to use
a catalytically inactive Cas9 (dCas9) to target piggyBac
insertions to a hypoxanthine phosphoribosyl transferase
(HPRT) gene in human cells (19). Surprisingly, instead of
targeting the HPRT locus, the dCas9-piggyBac chimera
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protected it from insertions. For targeting experiments, the
choice of the transposase moiety is limited by several fac-
tors. Although Tn5 is very active in vitro, and is used exten-
sively in bacteria, it transposes poorly in mammalian cells
(24). Sleeping Beauty is efficient in vivo but lacks an in vitro
system (9).While piggyBac is probably the most efficient for
gene delivery in vivo, it has a poor in vitro system (10,25),
which precludes the development of advanced applications
such as direct delivery of transpososomes.
Our model system is based on Hsmar1, a reconstituted
mariner-family transposon (26,27). In HeLa cells, Hsmar1
transposition is less than half as active as Sleeping Beauty
and piggyBac (16). Nevertheless, it is an excellentmodel sys-
tem for in vitro mechanistic studies as the reaction is 100%
efficient in vitro (28). Furthermore, if mariner transposo-
somes are assembled in vitro, they can be delivered to cells
directly [Ref. (29) and our unpublished experiment). Hs-
mar1 transposase also has much lower non-specific nucle-
ase activity than other mariner transposases such asMos1,
Mboumar1 and Himar1 (30–35). Here we show that the
Cas9 and Hsmar1 transposase moieties of a fusion protein
are both active and report a targeting efficiency of more
than 50%.
MATERIALS AND METHODS
DNA oligonucleotides and most dry chemicals were from
Sigma Aldrich. Enzymes were from New England Bio-
labs and DNA purification kits were from Qiagen. The nu-
cleotide sequences of all plasmids used in this work are given
in Supplemental Table S1. The -galactosidase assays were
as described by Miller (36). LB agar indicator plates con-
tained 40 g/ml X-gal, when present,.
For in vivo assays in Escherichia coli, dCas9 was ex-
pressed from derivatives of plasmid pdCas9 (37). When
present, CRISPR spacers were cloned into the BsaI site as
oligoduplexes (Supplemental Table S2). TheHsmar1 trans-
posase gene was added to the 5′- or 3′-end of the dCas9
gene by polymerase chain reaction (PCR) using pdCas9
and pRC880 as templates: transposase-dCas9, pRC2302;
dCas9-transposase, pRC2303. An oligoduplex encoding
spacer-7 was cloned into the CRISPR locus of these plas-
mids to produce pRC2304 and pRC2305, respectively. The
native wild-type transposase was expressed from pRC2306,
which is identical to pdCas9 except that the dCas9 gene is
replaced by the transposase gene.
The transcription-strength series of expression vectors
for Figure 2C and D was created using the constitutive pro-
moters described by Tellier and Chalmers (38). In the plas-
mid with the strongest promoter, P4 (pRC2309), the native
Streptococcus pyogenes Cas9 promoter in pdCas9 was re-
placed by Tellier-P2. In plasmid P3 (pRC2308) the S. pyo-
genes promoter was replaced by Tellier-P1. In plasmid P2
(pRC2307) the S. pyogenes promoter was deleted by inverse
PCR and residual transcription was from a cryptic pro-
moter(s). The plasmid with the lowest level of transcrip-
tion, P1 (pRC2311), was created by replacing themulti-copy
origin-of-replication in plasmid P3 (above) with a single-
copy origin-of-replication from a bacterial artificial chro-
mosome vector.
Hsmar1 transposase was expressed from pRC880 and pu-
rified as a maltose binding protein fusion by affinity chro-
matography as described (33,39). The expression vector
for the dCas9-transposase fusion protein was pRC2303 de-
scribed above.
The dCas9-transposase fusion-protein was expressed
from the constitutive promoter in pRC2303. The plasmid
was transformed into E. coli NiCo21 (New England Bio-
labs). A single colony was picked into a starter culture of
LB-Lennox supplemented with 30 g/ml chloramphenicol
and grown at 37◦C for 16 h with shaking at 250 rpm in
a baffled Erlenmeyer flask. The culture was diluted 1:100
into freshmedia and growthwas continued until the OD600
reached 0.5. The temperature was then reduced to 18◦C
and the incubation was continued for 16 h. Cells (500 ml)
were harvested by centrifugation at 4◦C and resuspended in
40 ml binding buffer (20 mM Tris, pH 8.0, 5 mM imida-
zole, 0.5 M sodium chloride, 2 mM dithiothreitol (DTT)).
All subsequent steps were carried out at 4◦C. Cells were
lysed by five passes through a French pressure cell at 16
000 psi and the extract was clarified by centrifugation at
40 000 × g for 30 min. The clarified extract was applied
to a 1 ml HisTrap HP column (GE Life Sciences) on an
AKTA FPLC (Amersham Pharmacia). The column was
equilibrated with binding buffer and loosely bound pro-
teins were eluted with 40 column volumes of wash buffer
(20 mM Tris at pH 8.0, 60 mM imidazole, 0.5 M sodium
chloride, 2mMDTT). The columnwas then developedwith
a 20 column-volume linear-gradient up to 1 M imidazole.
Peak fractions were pooled an analyzed by sodium dodecyl
sulphate (SDS) polyacrylamide gel electrophoresis (Supple-
mentary Figure S1). When required for in vitro reactions,
the sgRNA and Cas9-transposase were assembled into a ri-
bonucleoprotein complex by incubating for 20 min at room
temperature in dCT binding buffer (20 mMHEPES pH 7.5,
250mMpotassium chloride, 2mMMgCl2, 0.01%TritonX-
100, 0.1 mg/ml bovine serum albumin (BSA), 10% glycerol)
(40). This was done every time it was required immediately
before it was used.
The electrophoretic mobility shift assay (EMSA) bind-
ing buffers for the native transposase and the dCas9-
transposase were, respectively, [20 mM HEPES at pH 7.5,
100 mMNaCl, 2 mMDTT, 10% glycerol, 5% dimethyl sul-
foxide (DMSO), 5 mM CaCl2, 250 g/ml BSA] and [20
mM HEPES pH 7.5, 250 mM potassium chloride, 2 mM
MgCl2, 0.01% Triton X-100, 0.1 mg/ml BSA, 10% glyc-
erol]. Reactions (20 l) contained 10 nM of a Cy-5 la-
beled oligoduplex encoding either the transposon end or
the target of the sgRNA (Supplementary Table S3). Af-
ter addition of the dCas9-sgRNA-transposase complex,
the reactions were incubated for 20 min at 37◦C. Bind-
ing reactions with the native transposase were incubated
for 60 min at room temperature to be consistent with
our previous work. Binding reactions were loaded onto a
trisaminomethane/borate/ethylenediaminetetraacetic acid
(TBE)-buffered 7% polyacrylamide gel and electrophoresed
at 120 V. Gels were recorded on a Fujifilm FLA-3000 Fluo-
rescence Laser Imaging Scanner.
In vitro transposition reactions were performed as de-
scribed (33). The reaction buffer contained 25 mM Tris–
HCl at pH 8.0, 5% glycerol, 100mMsodium chloride, 2mM
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DTT, 2.5 mMMgCl2 and 6.5 nMof supercoiled pRC650 as
substrate. Transposition reactions (50 l) were initiated by
the addition of transposase and incubated for 4 h at 37◦C.
Reactions were made 0.4% in SDS and 19 mM in ethylene-
diaminetetraacetic acid (EDTA) and heat inactivated at
75◦C for 30 min. Samples (35 l) were electrophoresed on
a TBE-buffered 1.1% agarose gel at 60 V for 16–24 h. Gels
were stained with ethidium bromide and photographed. In
vivo transposition reactions in E. coliwere performed as de-
scribed (41). The reporter strain [E. coli RC5096, F- fhuA2
Δ(lacZ)r1 glnV44 e14-(McrA-) trp-31 his-1 rpsL104 xyl-7
mtl-2 metB1 Δ(mcrC-mrr)114::IS10 argE::Hsmar1-lacZ’-
kanR] was derived from ER1793 (New England Biolabs).
Targeted transposition experiments were based on a
well known ‘plasmid-hop’ assay e.g. (31). The transposon
donor plasmid was pRC704, which encodes an R6K ori-
gin of replication and a mini-Hsmar1 transposon with a
kanamycin resistance gene. The small target plasmid was
pRC2312, which is essentially a dimer of pBluescript II SK+
with one of the copies of lacZ removed. The large tar-
get was pRC2313, which is identical to the small target ex-
cept that a 4.5 kb fragment of non-specific DNA from the
E. coli chromosomal argE-H locus was inserted. Reactions
(15l) were performed in our standard transposition buffer
(25 mM Tris–HCl at pH 8.0, 5% glycerol, 100 mM sodium
chloride, 2 mM DTT, 2.5 mMMgCl2) with 9 nM of target
plasmid and 13.5 nM pRC1105 to provide a background
of non-specific DNA. Reactions were incubated for 20 min
at 37◦C, initiated by the addition of the transposon donor
plasmid (9 nM) and incubated for a further 24 h. Reactions
were brought to 50 l with NEB Cutsmart buffer, supple-
mented with five units of NheI and five units of lambda
exonuclease to degrade the non-specific plasmid. Digestion
was stopped by adding 15 l of stop solution (0.5 mg/ml
proteinase K, 0.1% SDS, 50 mM EDTA) and incubating at
60◦C for 2 h. DNA was purified using a spin column from
the Qiagen PCR Clean-up kit, which was eluted with 30 l
of EB (10 mM Tris–HCl, pH 8.5). A total of 3–10 l of the
reaction was transformed into chemically competent E. coli
NEB5 and plated on LB agar plates supplemented with 50
g/ml kanamycin, 100 g/ml ampicillin, 40 g/ml X-gal
and 0.1% lactose. Targeting efficiency (%) was calculated by
dividing the number of white colonies by the total number
of colonies and multiplying by 100. Target plasmids from
randomly selected white colonies were purified and the lo-
cation of the transposon insertion in lacZ was determined
by Sanger sequencing using the M13 reverse primer.
RESULTS
Selection of gRNAs and construction of transposase-dCas9
fusions
Since gRNAs do not all bind their targets equally well
(42) we screened ten candidates for their ability to inhibit
transcription of the target lacZ gene. Oligoduplex spacer
sequences, encoding candidate gRNAs, were ligated into
the CRISPR locus of plasmid pdCas9 (Figure 1A). Subse-
quent transcription and processing in vivo produces a ma-
ture gRNA, which forms a ribonucleoprotein complex with
dCas9. The relative locations and orientations of the se-
lected gRNA target-sequences are shown in Figure 1B. Es-
cherichia coliBL21 cells were transformed with each dCas9-
gRNA expression plasmids separately and spread on X-
gal indictor plates to test the ability of the gRNAs to in-
hibit transcription of lacZ. Only spacers 4 and 7 produced
completely white colonies (not shown). Because spacer-7 is
within the coding sequence of the gene, it was selected for
all further experiments. To create a fusion protein capable
of targeted transposition, theHsmar1 transposase gene was
added to the 5′- or the 3′- end of the dCas9 gene in pdCas9
(Figure 1A). Two versions of the fusion protein expression
vectors were created, one with and one without spacer-7.
The fusion-proteins are active in E. coli
To test whether the fusion proteins were still capable of
gRNA-mediated transcriptional repression, the four plas-
mids were transformed intoE. coliBL21 and the lacZ activ-
ity was measured using the Miller assay (Figure 2A). There
was little silencing with dCas9 or either of the fusion pro-
teins in the absence of the gRNA. In the presence of the
gRNA the N- and C- terminal dCas9 fusion proteins both
repressed lacZ expression effectively. We then used a bacte-
rial transposition assay to test whether the transposase do-
main retained activity (Figure 2B).We also tested a plasmid
in which the dCas9 gene in pdCas9 was substituted with
the transposase gene. This provided a positive control in
which transposase expression was driven by the same pro-
moter as the fusion proteins. The rate of transposition was
highest for the transposase-dCas9 plasmid, which has the
transposase fused to the N-terminus of Cas9. This result
should be interpreted with caution as Hsmar1 transposi-
tion is subject to over-production inhibition (OPI) whereby
an increase in the transposase concentration beyond a low
level decreases the rate of transposition (16,38). Since the
promoter on pdCas9 is relatively strong, the system will
be dominated by OPI. In the presence of the gRNA the
rate of transposition for the N- and C-terminal fusion pro-
teins decreased significantly (Figure 2B). If this result is in-
terpreted in terms of the OPI model, it indicates that the
gRNA increased the transpositional-potential of the sys-
tem, which decreased the rate of transposition on account
of OPI. Since the dCas9-transposase protein, which has
the transposase on the C-terminus of dCas9, had the best
transpositional-potential and the best transcriptional re-
pression in the Miller assay, it was selected for all further
experiments (Figure 2A and B).
To explore the relationships between the expression level
of the fusion protein and its activities, the native Cas9 pro-
moter in pdCas9 was replaced with promoters P4 to P1,
which are of progressively lower strength (38). As expected,
transcriptional repression by the fusion protein was highest
with the native Cas9 promoter and decreased progressively
with promoter strength (Figure 2C). In contrast, the rate of
transposition had an inverse relationship to the strength of
the promoter, consistent with the expected effects of OPI
mentioned above (16).
We also tested whether the non-replicating dCas9-
transpososome would target the lacZ gene after electropo-
ration into E. coli cells. We recovered kanamycin resistant
clones with chromosomal integrations (not shown). How-
ever, targeted integration into the lacZ gene was obscured
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Figure 1. Plasmid pdCas9 and the chromosomal lacZ target. (A) Plasmid pdCas9 (37) encodes a catalytically inactive Cas9 variant (dCas9) in which the
nuclease activity is abolished by the D10A and H840A mutations. Expression is driven by the strong native Cas9 promoter from Streptococcus pyogenes.
The spacer is the user-defined sequence that base pairs with the target site. (B) The target site for dCas9 binding was the Escherichia coli lacZ gene. Ten
candidate spacers were selected to target the promoter and early open reading frame of lacZ. Of these 10 candidates, only spacers 4 and 7 inhibited
transcription completely, as judged by a white colony on X-gal indicator plates.
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Figure 2. Fusion-protein activity in vivo. The Hsmar1 transposase gene
was added to the 5′- or the 3′- end of the dCas9 gene in pdCas9, which is il-
lustrated in Figure 1A. (A) The plasmidswere transformed intoEscherichia
coli BL21 and lacZ activity was measured using the Miller assay (36). The
lacZ- control was provided by E. coli NEB5, while LacZ+ is the activity
with the untransformedBL21 host. Proteinswere expressed fromplasmids:
dCas9, pdCas9 = pRC2301; transposase-dCas9, pRC2302; transposase-
dCas9-gRNA, pRC2304; dCas9-transposase, pRC2303; dCas9-gRNA-
transposase, pRC2305. (B) The relative rates of transposition supported
by the N- and C-terminal fusions was assayed in E. coli as described previ-
ously (41). The wild-type transposase was expressed from pRC2306, which
is identical to pdCas9 except that the dCas9 gene is replaced by the trans-
posase gene. Other protein expression vectors were as in part A. (C) The re-
lationship between lacZ repression and the fusion-protein expression level
was explored. The highest level of expression was with the native Cas9 pro-
moter form pdCas9. Promoters P4 to P1 were progressively weaker (38).
The expression vectors were: P1, pRC2311; P2, pRC2307; P3, pRC2308;
P4, pRC2309. (D) The relationship between the expression level and the
rate of transposition was explored. Owing to auto-inhibition (or OPI) the
highest rate of transposition was with the lowest expression level, as ex-
pected (16). Protein expression vectors were as in previous parts.
by a high background of random integrations, which are
a recurrent problem in other similar transposon-targeting
systems.
dCas9-transposase binds transposon ends and the gRNA tar-
get
The assembly pathway for the Hsmar1 transpososome and
its behavior in an EMSA is illustrated in Figure 3A and
B. Binding of the first transposon end to the transposase
dimer yields single-end complex 2 (SEC2). Recruitment of
a second end yields the paired-ends complex (PEC). This
would normally be followed by the first cleavage step of
the reaction, except that the binding buffer lacks the cat-
alytic magnesium ion. During electrophoresis, the PEC de-
cays into single-end complex 1 (SEC1) (16). When the puri-
fied dCas9-transposase is titrated into the reaction the dis-
appearance of the free transposon ends is accompanied by
the appearance of two clear shifted bands plus a third band
close to the bottom of the well (Figure 3C). This is broadly
similar to the behavior of the wild-type transposase except
that the complexes are further up the gel owing to the much
larger size of the fusion protein. The band that just enters
the gel above SEC2 might represent the PEC, which is de-
tected in some experiments with the wild-type transposase
(16).
To explore the binding ability of the dCas9 moiety of the
fusion protein, an EMSAs was performed with an oligodu-
plex complimentary to the spacer-7 sequence (Figure 3D–
F). Since this experiment was performed in vitro we used a
single-guide RNA (sgRNA) in which the tracrRNA and the
crRNA were joined in a single strand. In the absence of the
sgRNA, titration of the fusion protein produced a smear
with no clear bands (Figure 3D). Presumably, this indicates
weak interactions between the protein and the DNA, which
dissociate during electrophoresis. When the fusion protein
was provided with the sgRNA, two clear complexes were
formed (Figure 3E). The stoichiometry of the complexes is
unknown but they may correspond to a dimer of the fusion
protein bound by either one or two target oligoduplexes.
When we added unlabeled competitor DNA to the reaction
it had no effect, which indicates that the oligoduplex bind-
ing to the fusion protein is specific (Figure 3F).
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Figure 3. EMSA analysis of the dCas9-transposase fusion protein. (A) Illustration of protein–DNA complexes formed during the transposition reaction
and decomposition of the PEC during electrophoresis. (B) EMSA of purified Hsmar1 transposase on a TBE-buffered 7% polyacrylamide gel. Reactions
contained 10 nM of a 70 bp Cy5-labeled oligoduplex encoding a transposon-end. Bands were visualized on a Fujifilm FLA-3000 Fluorescence Laser
Imaging Scanner. (C) EMSA as in part B but with the indicated amounts of the dCas9-transposase fusion protein without sgRNA. The band marked ?,
just below the wells, might represent the PEC, which is detected with the wild-type transposase if the PEC is artificially stabilized (16). (D–F) the EMSAs
were as in part B but with the purified dCas9-transposase fusion protein with its sgRNA. Reactions contained 10 nM of a 70 bp Cy5-labeled oligoduplex
complementary to sgRNA-7. When present, the sgRNA was preassembled in a 1:1.5 molar excess to the protein prior to the EMSA. The non-specific
competitor plasmid was 1 g of pRC2301 per binding reaction.
In vitro transposition with the dCas9-transposase fusion-
protein
Since we had demonstrated DNA binding by the respec-
tive dCas9 and transposase moieties of the fusion protein,
we next wanted to examine the intermediates and products
of the in vitro transposition reaction. When the wild-type
transposase is incubated with a supercoiled substrate, exci-
sion of the transposon leaves behind the plasmid backbone,
which is an end product of the reaction and a convenient
measure of the efficiency (Figure 4). After excision, target
sites for integration are acquired by a random collision-and-
tracking mechanism (33). Titration of the reaction with the
wild-type transposase or dCas9-transposase yielded a very
similar range of products (Figure 4).Minor differences were
probably owing to the differences in the quality of the pu-
rified proteins. However, adding an oligoduplex encoding
the target of the sgRNA reduced the amount of protein re-
quired for the maximum production of backbone. It also
changed the amount and relative proportions of the reac-
tion products.Most noticeable is the accumulation of the re-
laxed substrate. This is an intermediate of the reaction gen-
erated by the first nick at one of the transposon ends (33,43).
The transition between the first nick and the second, which
completes cleavage at the transposon end, involves a signif-
icant conformational change (28,44). Since nicking is abso-
lutely dependent on PEC formation (39), the accumulation
of the relaxed intermediate shows that the dCas9 moiety of
the fusion protein can interact with its oligoduplex target
at the same time as the transposase moiety is engage in a
transposition reaction. Clearly, this is a prerequisite for suc-
cessful targeting.
Targeted transposition reactions in vitro
To test whether the dCas9-transposase protein could tar-
get transposon insertions to a specific site in vitro we used a
modification of the mini-transposon hop assay (31). In this
assay, transposase catalyses the movement of a transposon
encoding a kanamycin resistance gene onto a target plas-
mid, which in this case encodes the lacZ fragment and an
ampicillin resistance gene (Figure 5A). The target was de-
rived from a dimer of pBluescript in which one of the two
lacZ fragments had been removed. Since the plasmid has
two ampicillin genes and two origins, it has no essential re-
gions and can tolerate insertions anywhere. This allows un-
biased recovery of integration events. We refer to the mod-
ified pBluescript dimer as the small target. We also created
a larger target by adding 4.5 kb of DNA from the E. coli
arginine biosynthesis operon. In addition to the transpo-
son donor and target plasmids, transposition reactions also
contained a decoy plasmid which provides a background
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Figure 4. In vitro transposition assays with the dCas9-transposase. Transposition reactions were 50 l with 6.5 nM of supercoiled plasmid substrate
(pRC650). The reactions were initiated by adding transposase and incubated for 4 h at 37◦C. Reactions were deproteinated with proteinase K and SDS
and 20 l was electrophoresed on a TBE-buffered 1.1% agarose gel at 60 V overnight. Photographs of ethidium bromide stained gels are shown. When
present, the sgRNA was preassembled in a 1:1.5 molar excess to the protein prior to the reaction. Where indicated, reactions contained 10 nM of a 70 bp
oligoduplex complementary to the sgRNA.
level of non-specific DNA. The reactions were assembled
and then initiated by the addition of the transposon donor
plasmid.
Transposition reactions were performed with the wild-
type transposase and the dCas9-transposase fusion-protein
either without or with sgRNA-7, which is complementary
to the lacZ region of the target plasmids. The integra-
tion products were transformed into E. coli NEB5 and
plated on LB agar plates supplemented with ampicillin,
kanamycin and X-gal (Figure 5B and C). Double transfor-
mants containing the donor and target plasmids are not
recovered because the R6K origin of replication requires
the Pir protein. Transposition reactions with the wild-type
transposase or the dCas9-transposase fusion yielded very
fewwhite colonies (Figure 5B). This reflects the fact that the
lacZ fragment represents only about 1/650th of the DNA
sequences available for integration. In contrast, more than
half of the colonies are white when the dCas9-transposase
protein is provided with the sgRNA. The targeting effi-
ciency is plotted in Figure 5C where it is defined as the per-
centage of all colonies that were white.
In the case of the blue colonies, the transformants must
have contained plasmids with transposon insertions out-
side of the lacZα region. We therefore focused on the white
colonies and used DNA sequencing to determine the trans-
poson integration sites (Figure 5D). In pBluescript the
lacZα open reading frame (ORF) is engineered to include a
polylinker and it is therefore longer than the corresponding
region from the wild-type lacZ gene. The ORF also codes
for additional amino acids at the 3′-end that are not neces-
sary for alpha complementation (45). All in all, the target
region in pBluescript in which integration events will yield
a white phenotype is 315 bp long (Figure 5D). Within this
region there are 18 TA dinucleotides, which are required
for the integration of mariner transposons. Only eight of
these sites are represented among the 20 un-targeted in-
tegrations mapped for the wild-type transposase and the
dCas9-transposase fusion without the sgRNA (Figure 5D).
This is not unusual as mild integration bias is well docu-
mented for the mariner transposons, where preferred sites
are known as hot spots (46–48).
We next examined the lacZ integration sites targeted by
the dCas9-sgRNA-transposase. We found that all had oc-
curred at two adjacent TAdinucleotides located 18–22 bp to
one side of the sgRNA binding site (Figure 5D and E). On
the other side of the binding site there are TA dinucleotides
between 8 and 18 bp distant that were not used. The loca-
tion of the integration sites immediately to one side of the
binding site probably reflects constraints imposed by the rel-
ative orientations of the dCas9 and the transposase domains
and the length of the linker region. It will be interesting to
test the site-preference of the transposase-dCas9 fusion, in
which the positions of the domains are swappedwith respect
to the N- and C-termini of the protein.
DISCUSSION
Many attempts have been made to target transposon inser-
tions to specific genomic locations. For example, one com-
prehensive study ofSleeping Beauty targeting explored a va-
riety of approaches using direct protein-DNA binding do-
mains and protein-protein sandwich interactions (18). This
provided for a 10% targeting-efficiency to an artificially en-
gineered chromosomal target site. In another study, Gal4-
Mos1 transposase and Gal4-piggyBac transposase fusions
could be biased toward a UAS-containing target plasmid
with 12.7- and 11.6-fold efficiency, respectively, compared
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/15/8126/5523009 by U
niversity of N
ottingham
 user on 11 O
ctober 2019
8132 Nucleic Acids Research, 2019, Vol. 47, No. 15
Figure 5. Transposon targeting reactions. (A) Illustration of the transposon donor and target plasmids. The donor plasmid (pRC704) encodes anHsmar1
transposon with an R6K origin of replication and a kanamycin resistance gene. The target plasmid (pRC2312) is essentially a dimer of pBluescript with
one copy of the lacZ gene removed. Since the plasmid has two origins and to ampicillin markers it can tolerate transposon insertions anywhere. The
large target has an extra 4.5 kb of non-specific DNA. Reactions also contained a background of non-specific DNA. (B) Reactions were performed with
the indicated transposase proteins, transformed into Escherichia coli and plated on LB plus ampicillin, kanamycin and X-gal. Transposon integrations
into the lacZ gene yield white colonies. Integrations elsewhere yield lacZ+ colonies. (C) Targeting efficiency. Error-bars are standard error of the mean
where n = 6 biological replicates. Ordinary one-way ANOVA analysis: Small target; transposase versus dCas9-transposase, P = 0.95; transposase versus
dCas9-sgRNA-transposase, P = <0.0001; dCas9-transposase versus dCas9-sgRNA-transposase, P = <0.0001. Large target: transposase versus dCas9-
transposase, P = 0.14; transposase versus dCas9-sgRNA-transposase, P = <0.0001; dCas9-transposase versus dCas9-sgRNA-transposase, P = <0.0001.
(D) Ten white colonies were picked from the three sets of plates and the location of the transposon insertion determined by Sanger sequencing. (E) An
expanded view of the indicated area of the lacZ gene.
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to the native transposase (20). A ZFP-piggyBac transposase
fusion provided a targeting frequency of 74% in an in vivo
plasmid-to-plasmid assay. However, the native piggyBac
transposase also integrated into the samewindowwith a fre-
quency of 50% (49). In another in vivo plasmid-to-plasmid
assay, a Gal4-piggyBac transposase fusion was able to bias
integrations around a UAS-containing target plasmid with
∼4-fold enrichment. After engineering the HEK-293 cell
genome to contain 1 or 2 Gal4-UAS target sequences,Gal4-
piggyBac transposase integrated close to the target site 32%
of the time compared to 8% for native transposase (50). It
was also demonstrated that a TALE-piggyBac fusion could
direct insertions into the first intron of the human CCR5
gene, which was detected at a frequency of ∼0.010–0.014%
of total stably transfected cells (17). When the zinc-finger
protein zif268 was fused to the C-terminus of the ISY100
transposase and it was shown that 50% of all integrations
occurred within 20 bp of the target site. However, the target
site on the target plasmid was engineered to contain nine
tandemly repeated TANN transposase integration sites ad-
jacent to the ZFP binding site (22). In amore recent study, a
TALE-piggyBac transposase and ZFP-PB transposase fu-
sion could target and integrate transposon DNA into the
human HPRT gene at a frequency of 0.97 and 0.42%, re-
spectively (19).
The long dwell time of dCas9 at its target site makes it a
powerful tool for gene activation and repression (51). It is
also an attractive candidate for transposon targeting. How-
ever, one study reported that although piggyBac integra-
tions at a specific target site were enriched by zinc finger
and TALE protein-fusions, dCas9 appeared to protect the
locus (19). In the present work we have demonstrated that a
mariner transposon can be effectively targeted by dCas9 and
that protection from integration is probably therefore pecu-
liar to piggyBac or perhaps a property of the interdomainal
linker. In our case, we found that the targeted mariner in-
sertions were at two adjacent TA dinucleotides about 20 bp
5′ to the sgRNA binding site (Figure 5E). Other TA din-
ucleotides located between 31 and 34 bp 5′, and between 8
and 18 bp 3′, of the sgRNAbinding sites were not used. This
indicates that the integration site is tightly constrained.
The properties of the interdomainal linker and the in-
trinsic target-site preference of the transposase may both
contribute to the constrained selection of integration sites.
Most, if not all, DNA transposons have preferred target hot
spots. For example, there is one extremely hot spot forMos1
integration that attracts almost all events in the Tn9 chlo-
ramphenicol acetyl transferase gene (47). Hsmar1 trans-
posase is perhaps less biased but some sites are certainly less
preferred than others (48). The tight constraint on the inte-
gration site immediately to one side of the target has not
been observed in other similar systems (see below). While
these systems used relatively short flexible linkers, our linker
comprised of 187 amino acids encoding the E. coli thiore-
doxin protein, whichwe had previously been usedwith great
success in creating a single-chain transposase-dimer (28). A
linker of this length would be very long if it was extended.
However, since ours encoded elements of secondary and ter-
tiary structure it will be quite compact, and presumably rel-
atively resistant to proteolysis. Indeed, the structure of the
linkermay account for the tight constraint of the integration
site immediately to one side of the dCas9 binding site (Fig-
ure 5). However, since the two targeted TA dinucleotides
are 4 bp apart they will be on almost opposite faces of the
DNA helix. This indicates that the angular distribution is
not tightly constrained. It will be interesting to explore the
effect of different interdomainal linkers and the effect of
adding additional TA dinucleotides slightly closer or fur-
ther away from the dCas9 binding site.
In targeting experiments with other transposase-fusion
proteins the selection of integration sites was not tightly
constrained as observed here. When Mos1 or piggyBac
transposases were fused to Gal4 using a 22 amino acid
linker integration was enriched for sites about 900 bp away
from the Gal4 upstream activating sequence (UAS). In the
case of Mos1, 98% of the integrations were at a TA dinu-
cleotide 954 bp from the binding site (20). Such frequent use
of a site, almost 10 DNA-persistence-lengths away from the
Gal4-UAS, can not be explained by the constraints of the
binding moiety. Instead, a combination of factors may be
at work. For example, the short dwell time of DNA binding
proteins, which range from seconds tominutes, will increase
the local concentration of the transpososome, which may
then select a nearby hot spot. This scenariomay also explain
the partial enrichment of AAV Rep-Sleeping Beauty inte-
gration at a site 700 bp from the Rep recognition sequence
(52). In another report, fusing the piggyBac transposase to
zinc finger and TALE proteins with linkers as short as 15
amino acids enriched for integrations between 24 and 5000
bp from the binding site in the hypoxanthine phosphori-
bosyl transferase (HPRT) gene (17,19). Within this region,
integrations were biased toward the HPRT transcriptional
start site. This may be owing to the chromatin configuration
or topological changes in the DNA. For example, mariner
transposition is sensitive to supercoiling in the transposon
donor and the target (39,48).
In addition to the targeting experiments, we also com-
pared the reaction intermediates with the transposase and
the dCas9-transposase proteins (Figures 2 and 3). In the
EMSA, the nucleoprotein complexes were very similar (Fig-
ure 3). Likewise, in reactions with a plasmid substrate, the
kinetics of the reaction intermediates were similar (Figure
4). However, there was a slight delay between first and sec-
ond strand cleavage at the transposon end when the target
of the sgRNA was included in the reaction. Overall, it is
clear that the Hsmar1 transposase behaves normally when
fused to dCas9 and that dCas9 is therefore a promising sys-
tem for targeted integration.
The single biggest problem in targeted-transposition pro-
tocols is that successful targeting in a particular cell is usu-
ally accompanied by random integrations. It should be pos-
sible to minimize this problem by delivering the transposo-
some to the cells after in vitro assembly (29). However, to
overcome random integration events, it will be necessary to
control the timing of integration to allow an opportunity
for the targeting moiety to find its binding site. We are cur-
rently exploring strategies for the temporal control of trans-
poson integration. For example, the use of optogenetics to
insert a photo-labile amino acid analog in place of an essen-
tial amino acid in theHsmar1 transposase (53). Once these
methods have been established for Hsmar1, the principles
can be translated into Sleeping Beauty and piggyBac sys-
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tems, which are more efficient methods of gene delivery in
animal cells.
NOTE ADDED IN PROOF
While this article was in press an Epub (ahead of print) by
Strecker and colleagues reported that a CRISPR-associated
transposase from Scytonema hofmanni (ShCAST) catalyzes
site-specific RNA-directed integration (54). Similar to our
findings, integrations were unidirectional and located a
fixed distance to one side of the targeted DNA site. The
ShCAST is a homolog of the Tn7 transposase from E.
coli and their reactions are very similar except for the tar-
geting mechanism. The TnsD subunit of Tn7 uses a di-
rect sequence-specific protein-DNA interaction to target in-
tegrations into a unique attachment site on the chromo-
some ofE. coli andmany other bacteria [(55) and references
therein]. The ShCAST differs from Tn7 in that the function
of TnsD is performed by a Cas12K subunit using an RNA-
directed interaction.
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